ARCH Venture Partners

Founded in 1986, ARCH Venture Partners is a Chicago-based venture capital firm specializing in early-stage investments in life sciences and biotechnology. The firm originated from a collaboration between the University of Chicago and Argonne National Laboratory, aiming to commercialize groundbreaking scientific research.

ARCH is renowned for its hands-on approach, partnering closely with entrepreneurs and scientists to translate innovative research into viable companies. The firm focuses on areas such as gene editing, immunotherapy, synthetic biology, and precision medicine, supporting ventures from inception through growth stages.

With a global investment perspective, ARCH has established offices in Chicago, Seattle, San Francisco, and Dublin. The firm has raised multiple funds, including the recent ARCH Venture Fund XIII, exceeding $3 billion, to continue backing pioneering companies that address critical healthcare challenges.